Company
News from Hyglos Now Hyglos - Profos AG has been acquired by private investors
| Now Hyglos - Profos AG has been acquired by private investors |
|
|
|
The former biotech company Profos AG situated in the Biopark in Regensburg has been
acquired by new investors and starts from March 2009 as a new company Hyglos GmbH.
The new holders of the company are investors coming from science and industry (Hyglos
Invest GmbH and Mérieux Alliance).
The focus of Hyglos GmbH is the production and distribution of products and services developed within the last years on the basis of the patented phage-protein technology. Several projects have achieved production level and additionally to Hyglos established product portfolio with the main segments “EndoLine” and “Food Diagnostics” further product launches are planned. In August 2008, the long-term cooperation partner bioMérieux launched VIDAS® UP for the detection of E. coli O157:H7, the first assay in a new groundbreaking generation based on Hyglos technology. For customers and business partners little has changed besides of the new company data. For the future success of the new company the investment structure is advantageous for all parties: Scientific contributions foster new scientific cooperations and industrial partnership will open new market segments and improve customer access. Investment consulting will strengthen the financial situation and finally lead the new company to business success. About Hyglos GmbH Hyglos GmbH was founded in 2009 as the follow-up company of former Profos AG founded in 2000. Hyglos´ core competency is to exploit the principles of bacteriophage biology and the expert use of the proprietary phageprotein technology for pharmaceutical, diagnostic and research applications. For more information, call Hyglos GmbH at +49-941-942 620 or write to About Hyglos Invest GmbH Hyglos Invest GmbH was founded in 2009 and is the investor company for Hyglos GmbH. About bioMérieux A world leader in the field of in vitro diagnostics for 45 years, bioMérieux is present in more than 150 countries through 38 subsidiaries and a large network of distributors. bioMérieux provides diagnostic solutions (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. bioMérieux is listed on the NYSE Euronext Paris market (Code: BIM – Code ISIN: FR0010096479). Further information can be found at http://www.biomerieux.com/. |